AI Article Synopsis
- The study focused on analyzing gene expression in lung tissue from patients with systemic sclerosis-related interstitial lung disease (SSc-ILD) to identify molecular pathways involved in lung disease progression.
- Lung samples were collected from 28 SSc-ILD patients and 4 healthy controls, with findings showing distinct gene expressions linked to inflammation and fibrosis in the diseased lungs.
- Key identified genes correlated with worsening lung function and fibrosis, providing insights into potential therapeutic targets for managing SSc-ILD.
Article Abstract
Objective: Systemic sclerosis (SSc)-related interstitial lung disease (ILD) is one of the leading causes of mortality. We undertook this study to analyze the gene expression of lung tissue in a prospective cohort of patients with SSc-related ILD and to compare it with that in control lungs and with 2 prospective clinical parameters in order to understand the molecular pathways implicated in progressive lung disease.
Methods: Lung tissue was obtained by open lung biopsy in 28 consecutive patients with SSc-related ILD and in 4 controls. High-resolution computed tomography (HRCT) and pulmonary function testing (PFT) were performed at baseline and 2-3 years after treatment based on lung histologic classification. Microarray analysis was performed, and the results were correlated with changes in the HRCT score (FibMax) and PFT values. Quantitative polymerase chain reaction (qPCR) and immunohistochemistry were used to confirm differential levels of messenger RNA and protein.
Results: Lung microarray data distinguished patients with SSc-related ILD from healthy controls. In the lungs of patients with SSc-related ILD who had nonspecific interstitial pneumonia (NSIP), expressed genes included macrophage markers, chemokines, collagen, and transforming growth factor β (TGFβ)- and interferon (IFN)-regulated genes. Expression of these genes correlated with progressive lung fibrosis defined by the change in FibMax. Immunohistochemistry confirmed increased markers of collagen (COL1A1), IFN (OAS1 and IFI44), and macrophages (CCL18 and CD163), and the positive correlation with the change in FibMax was confirmed by qPCR in a larger group of SSc patients with NSIP. Several genes correlated with both the change in FibMax (r > 0.4) and the change in % predicted forced vital capacity (r < -0.1), including IFN and macrophage markers, chemokines, and heat-shock proteins.
Conclusion: These results highlight major pathogenic pathways relevant to progressive pulmonary fibrosis in SSc-related ILD: macrophage emigration and activation, and up-regulated expression of TGFβ- and IFN-regulated genes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4439004 | PMC |
| http://dx.doi.org/10.1002/art.38288 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparing three-dimensional zero echo time (3D-ZTE) lung MRI and chest CT in the evaluation of systemic sclerosis-related interstitial lung disease.
Eur Radiol
November 2024
Department of Rheumatology, Pamukkale University School of Medicine, Denizli, Turkey.
Objective: Systemic sclerosis (SSc) is a chronic disease that can cause interstitial lung disease (ILD), a poor prognostic factor in SSc patients. Given the concerns over radiation exposure from repeated CT scans, there is a growing interest in exploring radiation-free imaging alternatives like MRI for ILD evaluation. The aim of this study is to assess the efficacy of three-dimensional zero echo time (3D-ZTE) MRI in assessing SSc-related ILD compared to the thin-slice chest CT.
View Article and Find Full Text PDFB-Lines in the Assessment of Interstitial Lung Disease Associated with Scleroderma: The Role of Handheld Devices.
Diagnostics (Basel)
October 2024
Internal Medicine Department, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.
: Timely detection and aggressive management of interstitial lung disease (ILD) in systemic sclerosis (SSc) are essential to improving outcomes and reducing risks of irreversible lung injury. : to explore the usefulness of an ultraportable ultrasound device for the management of SSc-related ILD and to compare it with clinical and instrumental data. : A total of 19 consecutive SSc patients underwent a comprehensive pulmonary evaluation: clinical, pulmonary function tests (PFTs) (spirometry, DLCO), lung CT (1.
View Article and Find Full Text PDFNerandomilast Improves Bleomycin-Induced Systemic Sclerosis-Associated Interstitial Lung Disease in Mice by Regulating the TGF-β1 Pathway.
Inflammation
October 2024
State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, Tianjin, 300353, China.
Article Synopsis
- Systemic sclerosis (SSc) is a rare and complicated connective tissue disease, often leading to interstitial lung disease (ILD), which significantly increases mortality in affected patients.
- Current treatment options for SSc-ILD are limited, with nintedanib and tocilizumab being the only approved drugs, indicating an urgent need for new therapeutic strategies.
- Research shows that nerandomilast, a phosphodiesterase 4B inhibitor, effectively reduces skin and lung fibrosis in a mouse model and could be a promising candidate for treating SSc-ILD by targeting specific signaling pathways.
Assessing disease activity in scleroderma-related interstitial lung disease: a review and practical guide to management.
Monaldi Arch Chest Dis
September 2024
New Cross Hospital, Wolverhampton.
Systemic sclerosis (SSc) is a heterogeneous disease with a propensity to involve multiple organ systems. There is a significant proportion of these patients with interstitial lung disease (ILD) who are at risk of mortality and morbidity. There are limited available tools to assess the severity of parenchymal lung involvement and are subject to confounding factors, including the presence of pulmonary hypertension and concomitant smoking history.
View Article and Find Full Text PDFConcordance and Prognostic Relevance of Different Definitions of Systemic Sclerosis Interstitial Lung Disease Progression.
Am J Respir Crit Care Med
December 2024
Division of Pulmonology, Department of Neurosciences, Sense organs and Thorax, and.
Interstitial lung disease (ILD) in systemic sclerosis (SSc) is a common complication that has a varied progression rate and prognosis. Different progression definitions are available, including minimal clinically important worsening of FVC, EUSTAR (European Scleroderma Trials and Research Group) progression, OMERACT (Outcome Measures in Rheumatology Clinical Trials) progression, and Erice ILD working group progression. Pulmonary function and symptom changes may act as specific confounding factors when applying these definitions in SSc.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!